- Home
- JXJT vs BCDA Comparison
JXJT vs BCDA Comparison
Compare JXJT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXJT
- BCDA
- Stock Information
- Founded
- JXJT 2012
- BCDA N/A
- Country
- JXJT China
- BCDA United States
- Employees
- JXJT N/A
- BCDA N/A
- Industry
- JXJT Apparel
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- JXJT Consumer Staples
- BCDA Health Care
- Exchange
- JXJT Nasdaq
- BCDA Nasdaq
- Market Cap
- JXJT 11.5M
- BCDA 7.9M
- IPO Year
- JXJT 2012
- BCDA N/A
- Fundamental
- Price
- JXJT $1.57
- BCDA $2.60
- Analyst Decision
- JXJT
- BCDA Strong Buy
- Analyst Count
- JXJT 0
- BCDA 1
- Target Price
- JXJT N/A
- BCDA $25.00
- AVG Volume (30 Days)
- JXJT 36.7K
- BCDA 74.1K
- Earning Date
- JXJT 11-01-2024
- BCDA 11-06-2024
- Dividend Yield
- JXJT N/A
- BCDA N/A
- EPS Growth
- JXJT N/A
- BCDA N/A
- EPS
- JXJT 0.48
- BCDA N/A
- Revenue
- JXJT $31,840,588.00
- BCDA $428,000.00
- Revenue This Year
- JXJT N/A
- BCDA $6.92
- Revenue Next Year
- JXJT N/A
- BCDA N/A
- P/E Ratio
- JXJT $3.40
- BCDA N/A
- Revenue Growth
- JXJT N/A
- BCDA 0.71
- 52 Week Low
- JXJT $1.04
- BCDA $1.96
- 52 Week High
- JXJT $8.51
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- JXJT 38.73
- BCDA 46.60
- Support Level
- JXJT $1.40
- BCDA $2.39
- Resistance Level
- JXJT $1.75
- BCDA $2.84
- Average True Range (ATR)
- JXJT 0.14
- BCDA 0.17
- MACD
- JXJT -0.04
- BCDA -0.00
- Stochastic Oscillator
- JXJT 32.08
- BCDA 41.18
About JXJT JX Luxventure Limited
JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).